Download PDF

1. Company Snapshot

1.a. Company Description

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases.Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer.The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation.


The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc.with exclusive rights to CDX-301 and CD40 ligand; and Yale University.Celldex Therapeutics, Inc.


was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Show Full description

1.b. Last Insights on CLDX

Celldex Therapeutics' recent performance has been driven by several positive developments. The company has completed enrollment in its global Phase 3 studies, EMBARQ-CSU1 and EMBARQ-CSU2, of barzolvolimab in chronic spontaneous urticaria (CSU), with 1,939 patients enrolled across 43 countries and over 500 sites. Additionally, multiple presentations from its Phase 2 clinical trials of barzolvolimab have been accepted for presentation at the 2026 American Academy of Allergy, Asthma & Immunology's (AAAAI) Annual Meeting. Management will also participate in fireside chats at upcoming investor conferences. Analysts have a consensus rating of "Moderate Buy" on the stock, with seven assigning a buy rating. Institutional investors, including American Century Companies Inc. and Corient Private Wealth LLC, have recently increased their positions in the company.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026

Mar -01

Source: globenewswire.com

Card image cap

Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026

Feb -27

Source: globenewswire.com

Card image cap

Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Feb -25

Source: globenewswire.com

Card image cap

Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria

Feb -25

Source: globenewswire.com

Card image cap

Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab's First-in-Class and Best-in-Disease Profile

Feb -23

Source: globenewswire.com

Card image cap

Celldex to Present at Upcoming Investor Conferences

Feb -09

Source: globenewswire.com

Card image cap

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Short Interest Update

Jan -21

Source: defenseworld.net

Card image cap

Celldex Therapeutics SVPs Engage In Heavy Transactions

Jan -12

Source: fool.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (11.30%)

6. Segments

Novel Therapeutics

Expected Growth: 11.3%

Celldex Therapeutics' Novel Therapeutics segment growth of 11.3% is driven by increasing adoption of CDX-0158, a promising treatment for chronic refractory gout, and CDX-1140, a novel immunotherapy for various cancers. Strong clinical trial results, strategic partnerships, and expanding pipeline contribute to the segment's growth momentum.

7. Detailed Products

Glembatumumab vedotin

An antibody-drug conjugate designed to treat various types of cancer, including melanoma and breast cancer.

Varlilumab

A monoclonal antibody designed to treat various types of cancer, including melanoma, lung cancer, and kidney cancer.

CDX-0159

A monoclonal antibody designed to treat various types of cancer, including melanoma and breast cancer.

CDX-1140

A monoclonal antibody designed to treat various types of cancer, including breast cancer and lung cancer.

CDX-527

A monoclonal antibody designed to treat various types of cancer, including melanoma and breast cancer.

8. Celldex Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Celldex Therapeutics, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies for cancer and immunological disorders.

Bargaining Power Of Customers

Celldex Therapeutics, Inc. has a low bargaining power of customers due to the specialized nature of its products and the lack of alternative options for patients.

Bargaining Power Of Suppliers

Celldex Therapeutics, Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers for raw materials and equipment.

Threat Of New Entrants

Celldex Therapeutics, Inc. has a high threat of new entrants due to the growing demand for cancer and immunological disorder treatments and the presence of emerging biotech companies.

Intensity Of Rivalry

Celldex Therapeutics, Inc. operates in a highly competitive industry with many established players, leading to a high intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 0.59%
Debt Cost 3.95%
Equity Weight 99.41%
Equity Cost 11.94%
WACC 11.89%
Leverage 0.59%

11. Quality Control: Celldex Therapeutics, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
PTC Therapeutics

A-Score: 5.8/10

Value: 7.8

Growth: 5.6

Quality: 8.4

Yield: 0.0

Momentum: 9.5

Volatility: 3.3

1-Year Total Return ->

View Full Report
Stock-Card
Rhythm Pharma

A-Score: 4.6/10

Value: 6.0

Growth: 5.1

Quality: 4.1

Yield: 0.0

Momentum: 9.5

Volatility: 2.7

1-Year Total Return ->

View Full Report
Stock-Card
Ionis Pharmaceuticals

A-Score: 4.2/10

Value: 6.0

Growth: 1.1

Quality: 4.4

Yield: 0.0

Momentum: 10.0

Volatility: 4.0

1-Year Total Return ->

View Full Report
Stock-Card
Celldex Therapeutics

A-Score: 3.8/10

Value: 6.7

Growth: 3.0

Quality: 5.1

Yield: 0.0

Momentum: 5.0

Volatility: 3.0

1-Year Total Return ->

View Full Report
Stock-Card
Amicus Therapeutics

A-Score: 3.6/10

Value: 0.4

Growth: 7.4

Quality: 4.6

Yield: 0.0

Momentum: 5.5

Volatility: 3.7

1-Year Total Return ->

View Full Report
Stock-Card
Denali Therapeutics

A-Score: 3.3/10

Value: 6.7

Growth: 3.7

Quality: 4.5

Yield: 0.0

Momentum: 2.5

Volatility: 2.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

28.94$

Current Price

28.94$

Potential

-0.00%

Expected Cash-Flows